Skip to main content
img-impact-of-pan-kras-inhibitors-on-cancer-drug-discovery1920x640
Literature - Publication Review

The impact of pan-KRAS inhibitors on cancer drug discovery

The KRAS pathway was considered "undruggable". Read how Revvity's preclinical services helped Boehringer Ingelheim generate compounds to target this pathway.

In this literature review you will learn:

  • An overview of the challenges around KRAS inhibition
  • The approach the researchers took to develop and evaluate pan-KRAS inhibitors for their ability to combat carcinogenesis
  • Key findings from the study and the role that Revvity's cell panel screening services played

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

The impact of pan-KRAS inhibitors on cancer drug discovery